Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
This study is ongoing, but not recruiting participants.
First Received: December 8, 2005   Last Updated: July 16, 2008   History of Changes
Sponsored by: Allergopharma Joachim Ganzer KG
Information provided by: Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier: NCT00263640
  Purpose

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.


Condition Intervention Phase
Respiratory Hypersensitivity
 Biological: House dust mite, Acaroid
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Multicentre Randomised Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis

Resource links provided by NLM:

MedlinePlus related topics: Allergy Asthma
U.S. FDA Resources

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date: May 2005
Estimated Study Completion Date: February 2010
  Eligibility

Ages Eligible for Study:   6 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Bronchial asthma
  • Requirements for inhaled corticosteroid
  • Positive skin prick test to house dust mite
  • Positive radioallergosorbent test (RAST) to house dust mite
  • Positive provocation test result to house dust mite

Exclusion Criteria:

  • Serious chronic diseases
  • Other perennial allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263640

Locations
Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465
Sponsors and Collaborators
Allergopharma Joachim Ganzer KG
Investigators
Principal Investigator: Annemie Narkus, M.D. Allergopharma Joachim Ganzer KG
  More Information

Additional Information:
Leader in specific allergy research and therapy  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: Al0104av
Study First Received: December 8, 2005
Last Updated: July 16, 2008
ClinicalTrials.gov Identifier: NCT00263640     History of Changes
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:
House dust mite
Bronchial Asthma
Allergy
House Dust Mite Allergy

Study placed in the following topic categories:
Lung Diseases, Obstructive
Hypersensitivity
Aluminum sulfate
Respiratory Tract Diseases
Bronchial Diseases
 Lung Diseases
Hypersensitivity, Immediate
Asthma
Rhinitis
Respiratory Hypersensitivity

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Hypersensitivity
Immune System Diseases
Respiratory Tract Diseases
Bronchial Diseases
 Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on August 30, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services